Skip to main content

 

The Biosafety Advisory Council (BAC) is one of the two pillars (with the Service Biosafety and Biotechnology - SBB) of the scientific evaluation system that has been set up in Belgium to advise the Federal and Regional competent authorities about the biosafety of activities involving genetically modified organisms (GMOs) and/or pathogens.
 
The Council is composed of 12 effective and 12 substitute members designated by the different Regional and Federal competent authorities. It is assisted in its scientific work by external experts from academic institutions and by the SBB. The secretariat of the Council is ensured by the SBB.


The Council advises the authorities for all regulatory dossiers related to the deliberate release of GMOs in the environment or the placing on the market of GMOs and GMO-based products. The Council can be consulted by the Regions for contained activities involving GMOs and/or pathogens (i.e. activities taking place in laboratories, greenhouses, animal husbandries, production plants or hospital rooms).

Latest news

Advice on application GMFF-2022-9450 (genetically modified maize MON810) from Bayer intended for import and processing, food and feed
Advice on application EFSA-GMO-NL-2020-172 (genetically modified maize DP915635) from Pioneer intended for import and processing, food and feed
Advice on application EFSA-GMO-NL-2019-163 (genetically modified maize DP23211) from Pioneer intended for import and processing, food and feed
Advice on dossier B/BE/24/V3: Field trial (VIB) involving GM maize with improved digestibility
Advice on dossier B/BE/23/V4: Field trial (INARI Agriculture N.V.) involving GM maize gene edited for optimised plant architecture
Activity Report for 2022 of the Biosafety Advisory Council (in Dutch or in French)
Advice on application EFSA-GMO-DE-2018-149 (genetically modified maize Bt11 x MIR162 x MIR604 x MON 89034 x 5307 x GA21) from Syngenta intended for import and processing, food and feed
Advice on application EFSA-GMO-DE-2017-141 (genetically modified cotton COT102) from Syngenta intended for import and processing, food and feed
Advice on dossier B/BE/22/BVW6: Phase 3 clinical trial (Sarepta Therapeutics) involving a GM adeno-associated virus for treatment of Duchenne Muscular Dystrophy
Advice on dossier B/BE/22/BVW5: Phase 2 clinical trial (F. Hoffmann-La Roche Ltd) involving a GM adeno-associated virus for treatment of Duchenne Muscular Dystrophy